Cookie-Settings

We use cookies to give you the best experience possible with our website and to improve our communication with you. We consider your selection and will only use the data you have approved us to gather.

These cookies help making a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

These cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. With this information we can constantly improve the experience we offer on our website.

These cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.

DE
  • Home
  • About medac
  • Information for patients
  • Healthcare professionals
  • Products
  • Career opportunities
  • Media
  • medac Produktpalette

    medac’s complete range of products

    Here you can find an overview of all products offered by medac, listed alphabetically from A to Z. Please click on the respective medicinal product for more information.

    Use the quick search to look for a specific product.

    5-FU medac
    Ingredient
    5-fluorouracil
    5- FU medac 50mg/ml

    1 ml of solution for injection contains 50mg 5-fluorouracil

    PZN:
    03727369
    5- FU medac 50mg/ml

    1 ml of solution for injection contains 50mg 5-fluorouracil

    PZN:
    03728044
    5- FU medac 50mg/ml

    1 ml of solution for injection contains 50mg 5-fluorouracil

    PZN:
    03728156
    5- FU medac 50mg/ml

    1 ml of solution for injection contains 50mg 5-fluorouracil

    PZN:
    04142441

    Mechanism of action

    5-fluorouracil in itself is a non-antineoplastic synthetic fluorinated  pyrimidine derivate. After metabolism, cell division is inhibited by the active metabolites 5-fluorouridine triphosphate (FUTP) and 5-fluorodeoxyuridine monophosphate (FdUMP).

    Known mechanism of action

    • Blockade of DNA synthesis (inhibition of thymidylate synthase by FdUMP)
    • Inhibition of RNA synthesis (faulty structuring of RNA by incorporation of FUTP)
    • DNA strand breaks following incorporation of 5‑fluorodeoxyuridine triphosphate (phosphorylated FdUMP) in DNA

    The inhibitory effects are particularly evident in cells that grow rapidly and thus absorb 5‑fluorouracil to a greater extent.

    Adrimedac® 2 mg/ml solution for infusion
    Ingredient
    Doxorubicin hydrochloride
    Doxorubicin hydrochloride 2 mg/ml solution for infusion

    1 x 5 ml vial contains a total content of doxorubicin hydrochloride of 10 mg

    PZN:
    07698251
    Doxorubicin hydrochloride 2 mg/ml solution for infusion

    1 x 25 ml vial contains a total content of doxorubicin hydrochloride of 50 mg

    PZN:
    07698297
    Doxorubicin hydrochloride 2 mg/ml solution for infusion

    1 x  100 ml vial contains a total content of  doxorubicin hydrochloride of 200 mg

    PZN:
    07698274

    Mechanism of action

    Adrimedac® 2 mg/ml solution for infusion has a cytotoxic effect, inhibiting DNA and RNA synthesis through several mechanisms: intercalation between DNA bases, inhibition of various enzymes such as topoisomerase II, helicase and DNA and RNA polymerases and formation of free oxygen radicals.

    BCG-medac
    Ingredient
    BCG (Bacillus Calmette Guerin, seed RIVM)
    BCG-medac, powder and solvent for suspension for intravesical use

    1 vial contains: BCG (Bacillus Calmette Guérin) bacteria seed RIVM derived from seed 1173-P2. Package size: 1 vial

    PZN:
    02736461
    BCG-medac, powder and solvent for suspension for intravesical use

    1 vial contains: BCG (Bacillus Calmette Guérin) bacteria seed RIVM derived from seed 1173-P2. Package size: 1 vial

    PZN:
    02736484

    Mechanism of action 

    Immunostimulant

    Bendamustin medac
    Ingredient
    Bendamustine hydrochloride
    Bendamustine hydrochloride 2.5 mg/ml powder for concentrate for solution for infusion

    1 vial contains 25 mg bendamustine hydrochloride (as bendamustine hydrochloride monohydrate)

    PZN:
    11314144
    Bendamustine hydrochloride 2.5 mg/ml powder for concentrate for solution for infusion

    1 vial contains 100 mg bendamustine hydrochloride (as bendamustine hydrochloride monohydrate)

    PZN:
    11314204

    Mechanism of action

    Bendamustin medac is an alkylating substance containing the active substance bendamustine hydrochloride. The alkalising effect of bendamustine hydrochloride is essentially based on the cross-linking of DNA single and double strands, which impairs the synthesis and repair of DNA.

    Particularities:

    Bendamustine induces more rapid and frequent DNA double strand breaks compared to melphalan and cyclophosphamide.

    Moreover, the repair of bendamustine-induced DNA strand breaks has been shown to be more difficult and slower compared to cyclophosphamide and carmustine.

    Another advantage is that bendamustine does not show any cross-resistance with other alkylating agents.

    Bleomedac®
    Ingredient
    Bleomycin sulphate
    Bleomedac 15 mg powder for solution for injection

    1 vial contains 7.0 to 10.0 mg lyophilised bleomycin sulphate, equivalent to a standardised biological activity of 15 mg bleomycin (equivalent to 15,000 I.U. = 15 U (USP) bleomycin).

    PZN:
    02411351
    Bleomedac 30 mg powder for solution for injection

    1 vial contains 14.0 to 20.0 mg lyophilised bleomycin sulphate, equivalent to a standardised biological activity of 30 mg bleomycin (equivalent to 30,000 I.U. =  30 U (USP) bleomycin).

    PZN:
    02411368

    Mechanism of action

    Bleomycin has a cytostatic effect because of its specific binding to DNA, where it causes strand breaks.

    After administration, bleomycin forms an active complex with copper (Cu2+) and thus passes through the cell membrane into the cell interior. When the copper splits off in the cell plasma, bleomycin binds to DNA in the nucleus. Activated by free oxygen radicals, it induces strand breaks in the DNA. The greatest susceptibility is shown in cells in the G2 and M phases of the cell cycle.

    Capecitabin medac film-coated tablets
    Ingredient
    Capecitabine
    CAPECITABINmedac 150mg film - coated tablets

    1 film - coated tablet contains 150 mg capecitabine

    PZN:
    10002997
    CAPECITABINmedac 500mg film - coated tablets

    1  film - coated tablet contains 500 mg capecitabine

    PZN:
    10003011

    Mechanism of action

    Capecitabine is an orally administered precursor (prodrug) of 5‑fluorouracil (5-FU) and is activated in a three-step process in the liver and tumour tissue.

    1. After rapid absorption in the gastrointestinal tract, capecitabine in the liver is first metabolised by hepatic carboxylesterase to 5’-deoxy-5-fluorocytidine (5’-DFCR).

    2. 5’-DFCR is then converted to 5’-deoxy-5-fluorouridine (5’-DFUR) by cytidine deaminase, principally located in the liver and tumour tissues.

    3. The final catalytic activation occurs by thymidine phosphorylase, which is expressed in the tumour tissue in greater quantity. This transforms the 5’-DFUR into 5‑FU, resulting in cytostatic action affecting the tumour tissue in particular.

    Carbomedac® 
    Ingredient
    Carboplatin
    Carbomedac 10 mg/ml concentrate for solution for infusion

    1 vial of 15 ml concentrate for  solution for infusion contains 150 mg of carboplatin

    PZN:
    04172583
    Carbomedac 10 mg/ml concentrate for solution for infusion

    1 vial of 45 ml concentrate for solution for infusion contains 450 mg of carboplatin

    PZN:
    04172643
    Carbomedac 10 mg/ml concentrate for solution for infusion

    1 vial of 60 ml concentrate for solution for infusion contains 600 mg of carboplatin

    PZN:
    04172689

    Mechanism of action

    Carboplatin has biochemical properties similar to those of cisplatin, thus producing predominantly interstrand and intrastrand DNA crosslinks. Carboplatin exhibited comparable activity to cisplatin against a wide range of tumours regardless of implant site. Alkaline elution techniques and DNA binding studies have demonstrated the qualitatively similar modes of action of carboplatin and cisplatin. Like cisplatin, carboplatin induces changes in the superhelical structure of the DNA, consistent with a ‘DNA-shortening effect’.

    Carmustin Obvius
    Ingredient
    carmustine
    Carmustine Obvius 100 mg powder and solvent for concentrate for solution for infusion

    1 vial of powder for concentrate for solution for infusion contains 100 mg carmustine

    PZN:
    15613843
    Cecenu®
    Ingredient
    Lomustine
    Cecenu®  40 mg capsule

    1 capsule Cecenu contains 40 mg lomustine. Package size: 20 capsules

    PZN:
    08768798

    Mechanism of action

    After oral administration, lomustine breaks down spontaneously, first into a chlorethyl diazonium ion and then into a chlorethyl carbonium ion. Its cytostatic effect is the result of the alkylation of the O6 of guanine by the chlorethyl carbonium ion. Bifunctional alkylation leads to DNA crosslinking and induces apoptosis.

    CHEMOSAT®
    Chemosat

    Double balloon catheter 50 mm

    PN: 602002-01

    Chemosat

    Double balloon catheter 62 mm

    PN: 602001-01

    The Hepatic CHEMOSAT® Delivery System is a platform for the administration of chemosaturation therapy to the liver. The CHEMOSAT® system makes it possible to administer a chemotherapeutic agent (melphalan hydrochloride) to the liver, allowing for concentrated doses to be delivered while limiting systemic toxicity. CHEMOSAT® uses a procedure known as percutaneous hepatic perfusion (PHP). The system uses catheters placed to isolate the liver’s blood flow from the rest of the body and proprietary filters to reduce the concentration of the chemotherapeutic agent after it leaves the target organ. The blood which leaves the liver will be passed out of the body to filters which cover most of the removed chemotherapy drug before returning back to the body. Since the liver is isolated from the rest of the body, the chemotherapy drug could be given in higher concentration than it is possible with systemic chemotherapy. Treatment is carried out by administering the drug to the entire liver from both visible tumors and possibly undetected microtumors. A CHEMOSAT® procedure is minimally invasive and can be repeated. The CHEMOSAT® procedure is carried out in a trained hospital and it usually takes 3-5 hours. Most patients have to stay after that surgery for a few more days for observation in the hospital.

    Your Contact
    medac GmbH
    Head Office
    Theaterstraße 6 22880 Wedel Germany
    Nach oben